Treating Pancreatic Cancer with a Bacterial Vector: A Counter-Intiuitive Approach-Stephen T. Isaacs-05/01/2012 - 8:30am

Event Information
Event Topic: 
Treating Pancreatic Cancer with a Bacterial Vector: A Counter-Intiuitive Approach
Event Date: 
05/01/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
Stephen T. Isaacs
Event Speaker Title: 
Chairman, President and CEO
Event Speaker Company: 
Aduro BioTech
Event Speaker Bio: 

Stephen T. Isaacs

Stephen T. Isaacs is Chairman, President and CEO of Aduro BioTech. Prior to Aduro, Mr. Isaacs was founder (1991), President and CEO of Cerus Corporation (NASD: CERS), a biomedical products company commercializing the Intercept Blood Systems. During his tenure at Cerus, Mr. Isaacs grew the company from three to over two hundred and fifty employees. He raised over $650M, negotiated a $200M partnership with Baxter International, took Cerus public and developed two marketed products. In 2002, while still at Cerus, Mr. Isaacs initiated the current Aduro BioTech immunotherapy program. The immunotherapy technology is based on attenuated strains of Listeria monocytogenes, and Mr. Isaacs was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Prior to Cerus, Mr. Isaacs was the CEO of a number of small biotech companies where he negotiated contracts and partnerships with Cetus Corporation, Chiron Corporation, Eastman Kodak, Hoffmann-La Roche and Applied Biosystems. He is an international expert in psoralen photochemistry, and from 1978 to 1986 held a non-teaching faculty position in the Department of Chemistry at UC Berkeley. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. He holds a BA degree in Biochemistry from UC Berkeley, and had graduate training in organic chemistry in the PhD program in the Department of Chemistry at Berkeley. He is also deeply involved in volunteer work in Kasigau, Kenya through his family non-profit organization, ABE Club, where his family has worked for the past 8 years.

Event Details
Event Details: 

Aduro BioTech is a clinical stage company with a platform technology based on the bacterium Listeria monocytogenes. Aduro modifies Listeria at the genetic level to make it safe for human use as both a therapeutic and prophylactic vaccine for treating cancer, infectious diseases and for protective vaccines against a number of organisms. Aduro is currently conducting a randomized 90 patient Phase 2 clinical trial ( in metastatic pancreatic cancer and will soon start trials in both mesothelioma and glioblastoma. Aduro is also developing a protective vaccine against tularemia (rabbit fever) under contract with the Defense Threat Reduction Agency (DTRA). The Listeria technology was started at Cerus Corporation in 2002, spun out as Anza Therapeutics in 2007, nearly went out of business in 2008, and was acquired by Aduro BioTech in 2009. This roller-coaster history of the Listeria technology will be reviewed as part of the presentation as a lesson in both perseverance and the triumph of good science. More information can be found at